U.S. Medical Equipment Stock News

Serve Robotics (SERV) has posted FY 2025 results that highlight a small but growing top line alongside sizable losses, with Q4 revenue at about US$0.9 million and a quarterly net loss of roughly US$34.3 million, or EPS of US$0.46 loss, while trailing 12 month revenue sits at roughly US$2.7 million against a net loss of about US$101.4 million and EPS of US$1.63 loss. Over recent quarters the company has seen revenue move from around US$0.18 million in Q4 FY 2024 to US$0.88 million in Q4 FY...

Akebia Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$53.54 million versus US$57.34 million a year earlier, with net loss of US$9.05 million replacing prior net income of US$6.11 million. A recent proposal to increase authorized capital stock to 525,000,000 shares, including 500,000,000 common shares, adds a potential dilution and financing angle to Akebia’s weaker quarterly performance. Next, we’ll examine how the shift to a quarterly loss alongside...

If you are wondering whether MetLife at around US$78.82 offers fair value or a margin of safety, this article explains what the current price might be indicating. The stock has returned 10.7% over the last 30 days, while the 1-year return is 3.8% and the 3-year return is 67.2%. These figures can influence how investors view both potential upside and risk. Recent coverage has highlighted MetLife's position as a major US insurance company. Investors have been focusing on how interest rate...

If you are wondering whether UGI is attractively priced or just a value trap, starting with the current share price and valuation checks can help frame the picture. UGI closed at US$32.32, with recent returns showing a 10.4% decline over 7 days, 12.7% over 30 days, 14.1% year to date, and 3.6% over 1 year. This is set against a 31.7% gain over 3 years and an 11.3% decline over 5 years. These mixed return figures sit alongside ongoing investor attention on UGI as a regulated utility and...

Airbnb (ABNB) has wrapped up FY 2025 with fourth quarter revenue of US$2.8b and basic EPS of US$0.56, capping a year where trailing twelve month revenue reached US$12.2b and EPS came in at US$4.10. Over the past few quarters, revenue has moved from US$2.5b in Q4 2024 to US$4.1b in Q3 2025 before landing at US$2.8b in Q4 2025. Over the same stretch, quarterly EPS shifted from US$0.74 to US$2.25 and then to US$0.56, giving investors a clearer view of how profitability tracks Airbnb’s seasonally...

QuantumScape (NasdaqGS:QS) has started operations at its Eagle Line pilot-scale solid-state battery production facility. The company has recorded its first billings from ecosystem partners, initiating its licensing and royalty revenue stream. These developments represent a shift from pure development work to initial commercialization and monetization of its battery technology. QuantumScape focuses on solid-state lithium-metal batteries aimed at electric vehicles and related applications, a...

Amphastar Pharmaceuticals (AMPH) closed out FY 2025 with fourth quarter revenue of US$183.1 million and basic EPS of US$0.53, compared with prior year Q4 revenue of US$186.5 million and EPS of US$0.79, as trailing net profit margin moved from 21.8% to 13.6% over the last 12 months. Over the past six reported quarters, revenue has remained within a relatively narrow range of roughly US$170 million to US$192 million per quarter, while EPS has ranged from US$0.37 to US$0.83, giving investors a...

Cellebrite DI's Cellebrite Government Cloud platform has received FedRAMP High Authorization, the top federal cloud security standard. The U.S. Department of Justice acted as the sponsoring agency for this authorization. The approval covers handling of highly sensitive unclassified data for federal agencies. Cellebrite DI (NasdaqGS:CLBT) now has its Cellebrite Government Cloud cleared at the FedRAMP High level, placing it among a relatively small group of vendors that meet the federal...

If you are wondering whether Fortive at around US$60.90 is still a fair deal or already pricing in the story, this breakdown will help you size up what you are really paying for the stock. Over the shorter term, Fortive has posted returns of 1.9% over the last week, 7.1% over the last month, 9.9% year to date and 16.3% over the past year, which raises questions about how much of the current valuation is already reflected in the recent share price. Recent attention on Fortive has centered on...

For investors wondering if Brady's current share price still offers value or if most of the opportunity is already priced in, this article walks through what the numbers are really saying about the stock. Brady closed at US$79.53, with a 2.8% decline over the last 7 days and a 1.0% decline over 30 days, while still showing returns of 1.1% year to date and 9.9% over the last year. These price moves sit against a backdrop of ongoing investor interest in Commercial Services companies like Brady...

GLOBALFOUNDRIES stock might already be on your radar, but if you are wondering whether the recent excitement is backed up by value or just momentum, this is where the valuation story starts to take shape. At a last close of US$70.93, the stock shows returns of 9.8% over 7 days, 61.5% over 30 days, 92.4% year to date and 97.4% over the past year. This raises fair questions about how much future upside or downside is already reflected in the price. Recent coverage has focused on GLOBALFOUNDRIES...

Geron (GERN) is back in focus after its Q1 2026 earnings, where revenue and loss per share came in ahead of expectations, supported by RYTELO growth, reiterated full-year guidance, and pipeline updates. See our latest analysis for Geron. Despite the stronger Q1 update, Geron’s 1-day share price return of a 7.6% decline and 1-month share price return of a 16.1% decline suggest fading near-term momentum, while the 1-year total shareholder return of 15.9% and 3-year total shareholder return of a...

Jumia Technologies (NYSE:JMIA) just wrapped up FY 2025 with Q4 revenue of US$61.4 million and a basic EPS loss of US$0.08, alongside a trailing 12 month revenue base of US$188.9 million and a loss of US$61.6 million. Over the past six reported quarters, revenue has moved from US$36.3 million in Q1 2025 to US$61.4 million in Q4 2025, while quarterly net losses ranged between US$10.3 million and US$19.5 million. This sets the stage for a story that now hinges on how quickly margins can tighten...

In the first quarter of 2026, Energy Recovery, Inc. reported sales of US$9.71 million, a wider net loss of US$12.25 million, a US$1.66 million goodwill impairment, and announced upcoming CEO retirement alongside the resignation of its CFO. The company also withdrew its 2026 financial guidance amid Middle East uncertainty, even as new product launches and desalination demand supported revenue growth. Next, we’ll examine how the withdrawal of 2026 guidance reshapes Energy Recovery’s investment...

Wondering if Compass Minerals International at US$28.24 is genuinely good value or just riding a trend? This article breaks down what the current price could mean for you. The stock has returned 5.7% over the last 7 days, 23.1% over the last 30 days, 42.2% year to date and 57.2% over the last year. The 3 year and 5 year returns sit at 10.9% and 56.2% declines respectively. Recent coverage has focused on Compass Minerals International's position within the broader materials sector and how...

In late April 2026, Phathom Pharmaceuticals reported that its first-quarter net loss narrowed to US$30.37 million from US$94.32 million a year earlier, while maintaining full-year 2026 net revenue guidance of US$320 million to US$345 million and expecting operating profitability, excluding stock-based compensation, to begin in the third quarter of 2026. The company also disclosed a change in how it classifies certain third-party costs starting January 1, 2026, which could make future margins...

Backblaze, Inc. recently reported first-quarter 2026 results, with sales rising to US$38.67 million and its net loss narrowing to US$6.15 million, while also issuing revenue guidance of US$39.8 million to US$40.2 million for the second quarter. The company also raised its full-year 2026 revenue outlook to a range of US$161.5 million to US$163.5 million, signaling growing confidence in its business trajectory. Next, we'll examine how Backblaze's improved quarterly loss and higher full-year...

ANI Pharmaceuticals (ANIP) FY 2025 earnings snapshot ANI Pharmaceuticals (ANIP) just wrapped up FY 2025 with Q4 revenue of US$247.1 million and basic EPS of US$1.23, capping a year in which trailing twelve month revenue reached US$883.4 million and basic EPS came in at US$3.50. Over recent quarters, revenue has moved from US$190.6 million in Q4 2024 to US$247.1 million in Q4 2025, while quarterly basic EPS shifted from a loss of US$0.55 to a profit of US$1.23, pointing to a very different...

Fluor's FY 2025 headline numbers Fluor (FLR) has just posted a mixed FY 2025 finish, with fourth quarter revenue of US$4.2b and a reported loss of US$1.6b, translating to basic EPS of US$9.86. The trailing twelve months show revenue of US$15.5b and a small net loss of US$51m, or basic EPS of US$0.31. The company has seen quarterly revenue move between US$3.4b and US$4.3b over the past six reported periods. EPS has swung from a gain of US$14.91 in Q2 2025 and US$10.58 in Q4 2024 to losses in...

Starwood Property Trust (STWD) just wrapped up FY 2025 with fourth quarter revenue of $148.8 million and basic EPS of $0.26, setting the tone for how investors will read the full year. The company has seen quarterly revenue move from $91.5 million in Q4 2024 to a range of $125.7 million to $148.8 million through 2025, while basic EPS has moved between $0.19 and $0.38 over the same stretch. This gives you a clear view of how the top line and per share results have tracked into this latest...

Astrana Health (ASTH) has wrapped up FY 2025 with fourth quarter revenue of US$950.5 million and basic EPS of US$0.12, alongside trailing 12 month revenue of about US$3.2 billion and EPS of US$0.46. This gives investors a clear read on both the latest quarter and the full year run rate. Over recent periods the company has seen quarterly revenue move from US$478.7 million in Q3 2024 to US$665.2 million in Q4 2024 and then into the US$620.4 million to US$956.0 million range through FY 2025,...

Wondering if Sempra at around US$91.57 is offering fair value or if you are paying up for recent momentum? This article breaks down what the current price might really mean for you. The stock has seen mixed moves recently, with a 3.7% decline over the last week and a 7.0% decline over the last month, while still showing returns of 2.1% year to date, 24.5% over 1 year, 31.2% over 3 years and 55.7% over 5 years. Recent attention on Sempra has been driven by ongoing interest in utilities that...

Ascendis Pharma (NasdaqGS:ASND) has just posted its Q1 2026 numbers, with revenue of €246.6 million and basic EPS of €10.2, alongside trailing twelve month revenue of €865.8 million and basic EPS of €8.12. Over the past year, revenue has moved from €363.6 million in Q4 2024 to €865.8 million on a trailing basis, while basic EPS has shifted from a trailing loss of €6.53 to positive €8.12. This sets up a quarter where reported profitability and revenue scale give investors a clearer view of how...

If you are wondering whether Becton Dickinson stock is offering good value right now, a good starting point is to line up its recent share performance against what investors are paying for the business. The stock last closed at US$153.26, with returns of 2.8% over the past week, a 1.1% decline over 30 days, a 21.4% decline year to date, and an 18.8% gain over the past year, which gives a mixed picture of sentiment and risk. Recent news coverage around Becton Dickinson has focused on its role...